Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

114.82 -0.94 (-0.81%)
Streaming Delayed Price Updated: 3:32 PM EDT, Sep 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
64 65 Next >
Gilead's Aggressive Push Beyond HIV Treatments - Plans To Increase Cancer-Focused CAR-T Treatment Production
Gilead Sciences plans to quadruple cell therapy cancer treatment production by 2026. With a focus on CAR-T treatments like Yescarta and Tecartus, Gilead aims to diversify into oncology. Anticipating a... 
Via Benzinga
If You Invested $100 In This Stock 20 Years Ago, You Would Have $1,100 Today
 
Via Benzinga
Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer
From Gilead Sciences, Inc.
Via Business Wire
3 Dividend Stocks to Buy Hand Over Fist in March
Income investors might want to load up on these great dividend stocks. 
Via The Motley Fool
The AI Race Gets Litigious
We've also got a look at the role of patents in pharmaceuticals and the "patent cliff" looming over the next decade. 
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
Balancing Dividends and Fundamentals: The Case of NASDAQ:GILD.
Exploring GILEAD SCIENCES INC (NASDAQ:GILD)'s dividend characteristics. 
Via Chartmill
$1000 Invested In This Stock 20 Years Ago Would Be Worth $11,000 Today
 
Via Benzinga
FDA Conditionally Approves Expanded Use Of BeiGene's Combination Drug For Certain Type Of Blood Cancer
FDA grants accelerated approval to BeiGene's Brukinsa for relapsed/refractory follicular lymphoma. Approved in combination with Roche's Gazyva after two or more lines of therapy. Brukinsa, priced at... 
Via Benzinga
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley
Morgan Stanley initiates coverage on Arcellx. Uncover the potential of ddBCMA in blood cancer treatment, featuring a differentiated CAR-T platform. Analysts project $5 billion in peak sales. 
Via Benzinga
Promising HIV Treatment: Phase 2 Clinical Trial Success for Gilead's and Merck's Combo Therapy
Gilead Sciences and Merck's Phase 2 study on islatravir and lenacapavir combo for HIV shows 94.2% viral suppression at 24 weeks. Potent antiviral activity revealed. 
Via Benzinga
Biktarvy® Demonstrates High Rates of Viral Suppression in People With HIV and Comorbidities
From Gilead Sciences, Inc.
Via Business Wire
Biogen's Spinraza For Muscle Movement Disorder Shows Improved Motor Function In Infants, Toddlers
Biogen's latest SMA research! Interim data from the RESPOND study reveals promising outcomes with SPINRAZA treatment. Learn about reduced NfL levels and the impact on infants and children with spinal... 
Via Benzinga
Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24
From Gilead Sciences, Inc.
Via Business Wire
Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers
From Gilead Sciences, Inc.
Via Business Wire
New Real-World Data Further Support the Use of Veklury® (Remdesivir) for People Hospitalized With COVID-19
From Gilead Sciences, Inc.
Via Business Wire
Gilead’s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health
From Gilead Sciences, Inc.
Via Business Wire
Hidden Gems: 7 Oversold Stocks Ready for a Major Rebound
While red ink signals danger, for these oversold stocks ready for rebound, they could imply upside opportunities. 
Via InvestorPlace
Crucial Battle Over Healthcare Mandates: Biden Administration Defends Preventive Care Coverage Amidst Legal Challenges
The Biden administration wants insurers to cover preventive care, facing opposition from businesses led by Braidwood Management. 
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay Therapeutics, Inc. (Nasdaq – CBAY), Everi Holdings Inc. (NYSE – EVRI), Sterling Check Corp. (Nasdaq – STER), Societal CDMO Check Corp. (Nasdaq – SCTL)
From Brodsky & Smith LLC
Via GlobeNewswire
Gilead Announces Funding Initiative to Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S.
From Gilead Sciences, Inc.
Via Business Wire
U.S. FDA Approves Expanded Indication for Gilead’s Biktarvy® to Treat People with HIV with Suppressed Viral Loads, Pre-existing Resistance
From Gilead Sciences, Inc.
Via Business Wire
Gilead to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024
From Gilead Sciences, Inc.
Via Business Wire
Week In Review: AlphaGen And ArtBio Form China-US Radioligand Partnership
Shanghai AlphaGen Therapeutics and ArtBio forged a far-reaching agreement to expand ArtBio’s market and develop new radioligand therapies. Additionally, Biocytogen Pharma signed an antibody... 
Via Talk Markets
3 Dividend Stocks That Are No-Brainer Buys Right Now
These stocks check off multiple boxes for investors. 
Via The Motley Fool
History Says the Nasdaq Will Keep Soaring in 2024 -- and Wall Street Thinks This High-Yield Dividend Stock Could Jump Nearly 20%
This biotech stock could be poised for a nice rebound if analysts are right. 
Via The Motley Fool
3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024
With new innovation and high demand, biotech stocks could offer some of the most explosive opportunities of the year. 
Via InvestorPlace
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
Stock Alert: 3 Market Giants on the Brink of Monumental Rallies
These are the stocks to buy to unlock the secrets of market giants in various industries for monumental growth and returns. 
Via InvestorPlace
From Zero to Hero: 7 Stock Losers That Could Turn Things Around in 2024
Although these companies suffered earlier, they could become stock turnarounds as investors recognize their potential. 
Via InvestorPlace
Why Is Gilead Sciences Stock Trading Lower Today?
Gilead Sciences' global enrollment pause in magrolimab solid tumor studies. FDA issues partial clinical hold. Explore the impact on ongoing trials. 
Via Benzinga
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
64 65 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.